Autoimmune Disorders

ClinicalJuly 20, 2026

Study Identifies Key Genes and Potential Therapies in Myasthenia Gravis via Lipid Metabolism Regulation

The study identified IRS2 and ALDH2 as key genes linked to lipid metabolism dysregulation in myasthenia gravis, with potential therapeutic candidates including metformin and cyclophosphamide.

Companies

Assets

Recent signals(8)

Efgartigimod shows potential as maintenance therapy for iTTP in pilot study

VIVACITY-MG3 Study Reveals High Healthcare Costs in Generalized Myasthenia Gravis Patients Treated with Nipocalimab

Study Identifies Key Genes and Potential Therapies in Myasthenia Gravis via Lipid Metabolism Regulation

Study on Crisaborole Ointment and Laser Therapy for Non-Segmental Vitiligo

FDA Grants Priority Review for VYVGART HYTRULO Supplement by ARGENX

FDA Accepts Supplement for LEQSELVI (Deuruxolitinib Phosphate) by Sun Pharma

Nipocalimab (Imaavy) Approved for Generalised Myasthenia Gravis Treatment

FDA Accepts Supplement Application for ENSPRYNG (Satralizumab)

Upcoming catalysts

Indications

Get signals before the market moves